Atlas Enterprises Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Atlas Enterprises Pharmaceutical Export Portfolio Dataset — 4 Products, $41.3K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Atlas Enterprises — Pharmaceutical Exporter Profile (2026) | 4 Products, $41.3K Trade | TransData Nexus

Atlas Enterprises

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $41.3K Total Trade · DGFT Verified

Atlas Enterprises is an Indian pharmaceutical exporter with a total trade value of $41.3K across 4 products in 1 therapeutic categories. Based on 41 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Fludarabine ($24.4K), Cladribine ($8.6K), Cabozantinib ($6.1K).

Atlas Enterprises — Export Portfolio & Destination Treemap

Atlas Enterprises pharmaceutical export portfolio — 4 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Atlas Enterprises? — Company Overview & Market Position

Atlas Enterprises, established in 2019, is a privately held pharmaceutical company headquartered in Nagpur, Maharashtra, India. The company specializes in the export, trading, and third-party manufacturing of a diverse range of pharmaceutical products, including tablets, capsules, syrups, and injections. With a mission to make healthcare accessible and affordable globally, Atlas Enterprises has built a reputation for delivering high-quality medicines to various international markets.

The company operates with a dedicated team of professionals, with employee numbers ranging from 11 to 50. Atlas Enterprises is registered under the Goods and Services Tax (GST) with the number 27ABPFA3473M1ZV, indicating its compliance with Indian tax regulations. The firm's Import Export Code (IEC) is ABPFA3473M, facilitating its international trade activities. For more information, the company's official website is https://atlasexporter.com/.

What Does Atlas Enterprises Export? — Product Portfolio Analysis

Top Products by Export Value

1Fludarabine$24.4K 2

Product Portfolio — Top 4 by Export Value

Atlas Enterprises exports 4 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Fludarabine	Advanced Oncology	$24.4K	11	0.8%	6
2	Cladribine	Advanced Oncology	$8.6K	7	3.7%	5
3	Cabozantinib	Advanced Oncology	$6.1K	18	4.8%	6
4	Axitinib	Advanced Oncology	$2.1K	5	2.3%	11

Atlas Enterprises exports 4 pharmaceutical products across 1 therapeutic categories with a total export value of $41.3K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Atlas Enterprises — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Atlas Enterprises operates manufacturing facilities in Nagpur, Maharashtra, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. While specific details regarding plant capacities and certifications are not publicly disclosed, the company emphasizes its commitment to quality and compliance with international standards.

3Key Leadership

The leadership team at Atlas Enterprises is headed by CEO Vikram Khangan, who plays a pivotal role in steering the company's strategic direction and operations. Under his guidance, the company has expanded its global footprint and enhanced its product offerings. Specific information regarding other key executives, such as the Chief Financial Officer (CFO), is not publicly available.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Atlas Enterprises Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Atlas Enterprises has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company is fully licensed by the State Food and Drug Administration (FDA) in India, ensuring compliance with national regulatory standards. Additionally, Atlas Enterprises is registered with various Export Promotion Councils (EPCs) in India, such as PHARMEXCIL and FIEO, and holds a One Star Export House status from the Directorate General of Foreign Trade (DGFT), reflecting its commitment to international trade standards.

2Emerging Markets

Atlas Enterprises has made strategic inroads into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's adherence to international standards and its registration with various EPCs in India, such as PHARMEXCIL and FIEO, facilitate its expansion into these markets. While specific details regarding WHO prequalification are not publicly disclosed, the company's compliance with global standards positions it favorably for market access in these regions.

3Geographic Strategy

Atlas Enterprises — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Atlas Enterprises' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's compliance with Indian FDA regulations and its registration with various EPCs suggest a commitment to meeting international standards, which is essential for accessing regulated markets like the United States.

2WHO & EU GMP

Atlas Enterprises' adherence to international standards is indicated by its registration with various Export Promotion Councils (EPCs) in India, such as PHARMEXCIL and FIEO, and its One Star Export House status from the Directorate General of Foreign Trade (DGFT). However, specific information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly disclosed.

3CDSCO & Indian Regulatory

Atlas Enterprises holds a manufacturing license from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's compliance with Indian regulatory standards is further evidenced by its GST registration and IEC, facilitating its domestic and international trade operations. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly available.

Atlas Enterprises — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the Advanced Oncology therapeutic category, Atlas Enterprises faces competition from both domestic and international pharmaceutical companies. While specific market share data is not publicly available, the company's focus on this specialized segment allows it to leverage its expertise and resources effectively. However, the lack of diversification may expose the company to market fluctuations within the oncology sector.

2Key Differentiators

Atlas Enterprises' key differentiators include its specialized focus on the Advanced Oncology therapeutic category, a comprehensive range of high-quality pharmaceutical products, and a commitment to making healthcare accessible and affordable globally. The company's adherence to international standards and its registration with various EPCs in India further enhance its competitive position.

3Strategic Position

Atlas Enterprises currently focuses on the export and trading of finished pharmaceutical formulations, primarily in the oncology segment. The company's strategic direction emphasizes quality, compliance with international standards, and global accessibility. Future outlooks may involve expanding its product portfolio, diversifying into other therapeutic areas, and enhancing its presence in emerging markets to mitigate risks associated with market concentration.

Buyer Due Diligence Brief — Evaluating Atlas Enterprises as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Atlas Enterprises has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $41,000 USD across 41 shipments. The company's portfolio is concentrated in the Advanced Oncology therapeutic category, with top products including Fludarabine, Cladribine, Cabozantinib, and Axitinib. While specific reliability indicators are not publicly available, the company's adherence to international standards and its registration with various EPCs in India suggest a commitment to quality and reliability.

2Certifications to Verify

Importers should verify the following certifications when considering Atlas Enterprises as a supplier:

FDA Facility Registration: Confirm the company's registration with the U.S. Food and Drug Administration (FDA) to ensure compliance with U.S. regulatory standards.

WHO-GMP Certification: Verify the company's adherence to World Health Organization (WHO) Good Manufacturing Practice (GMP) standards to ensure product quality and safety.

Frequently Asked Questions — Atlas Enterprises

How many pharmaceutical products does Atlas Enterprises export from India?

Atlas Enterprises exports 4 pharmaceutical products across 1 therapeutic categories. The top exports are Fludarabine ($24.4K), Cladribine ($8.6K), Cabozantinib ($6.1K), Axitinib ($2.1K). Total export value is $41.3K.

What is Atlas Enterprises's total pharmaceutical export value?

Atlas Enterprises's total pharmaceutical export value is $41.3K, based on 41 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Atlas Enterprises cover?

Atlas Enterprises exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 4 products).

Get Full Atlas Enterprises Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.